In congenital dystrophic variety of epidermolysis bullosa, mutation is seen in the gene coding for –
**Question:** In congenital dystrophic variety of epidermolysis bullosa, mutation is seen in the gene coding for -
A. COL7A1
B. COL17A1
C. COL14A1
D. COL14A2
**Core Concept:**
Epidermolysis bullosa (EB) is a group of genetic disorders characterized by blistering of the skin and mucous membranes due to a defect in the skin's structure and function. This can be classified into different types based on the location and severity of the blisters. Congenital dystrophic epidermolysis bullosa (CDEB) is a severe form of EB that presents within the first few days of life.
**Why the Correct Answer is Right:**
In the case of CDEB, the genetic defect lies in the COL7A1 gene, which codes for the protein called type VII collagen. Type VII collagen is a crucial component of the anchoring fibrils, which are responsible for anchoring the epidermis (the outermost layer of the skin) to the dermis (the deeper layer of the skin). The anchoring fibrils provide mechanical strength and stability to the skin, and any deficiency or mutation in these anchoring fibrils leads to the characteristic blistering and fragility seen in EB.
**Why Each Wrong Option is Incorrect:**
- COL17A1 (option B): This gene codes for type XVII collagen, which is not involved in anchoring fibrils or the structure of the epidermis.
- COL14A1 (option C): This gene codes for type XIV collagen, which is also not involved in anchoring fibrils or the structure of the epidermis.
- COL14A2 (option D): This gene codes for type XIV collagen, which is not involved in anchoring fibrils or the structure of the epidermis.
**Clinical Pearl:**
Understanding the molecular basis of Epidermolysis bullosa is crucial for healthcare professionals to provide appropriate counseling to patients and families, as well as to predict the severity and prognosis of the disease. In addition, knowledge of the specific gene mutation can guide the choice of targeted therapies in the future, as gene therapy approaches are being explored for the treatment of EB.